return to news
  1. Sun Pharma Q4 Results: Check date, time, dividend update, past performance and share price trend

Market News

Sun Pharma Q4 Results: Check date, time, dividend update, past performance and share price trend

Journalist Kamal Joshi, former Republic TV and latestly editor, now associated with Upstox

2 min read | Updated on May 12, 2026, 11:33 IST

SUMMARY

Sun Pharma Q4 Results: The stock had hit its 52-week high of ₹1,885.80 per share on May 11, 2026, while its 52-week low of ₹1,548 apiece was recorded on September 26, 2025.

Stock list

Sun Pharma is the world’s leading speciality generics company. | Image: sunpharma.com

Sun Pharma is the world’s leading speciality generics company. | Image: sunpharma.com

Sun Pharma Q4 results: Sun Pharmaceutical Industries, a speciality generic pharmaceutical company, will declare its latest set of numbers for the January-March quarter of the financial year 2025-26 on May 22.
Open FREE Demat Account within minutes!
Join now

In an exchange filing, the company said that its board of directors will meet on Friday, May 22, to "consider and approve audited standalone and consolidated financial results for the quarter and year ended 31 March 2026."

The board will also consider and recommend the final dividend, if any, for FY26 for approval of the shareholders at the forthcoming annual general meeting (AGM).

Sun Pharma Q4 results date and time

Sun Pharma will announce the fourth quarter FY26 results and recommend a dividend, if any, on Friday, May 22, 2026. The pharmaceuticals player has not announced the time to release its results. In Q3, earnings were released during the market hours.

Sun Pharma share price

Shares of Sun Pharma were trading flat at ₹1,871.60, down 0.06%, apiece on the NSE on Tuesday, May 12 at 11:32 am. Its market capitalisation stands at ₹4,49,107.52 crore.

The stock had hit its 52-week high of ₹1,885.80 per share on May 11, 2026, while its 52-week low of ₹1,548 apiece was recorded on September 26, 2025.

The scrip has gained 2.78% in the past week and 13.09% in a month. Year-to-date, it has advanced 8.74%.

How did Sun Pharma perform in Q3 FY26?

The consolidated net profit of Sun Pharmaceutical Industries rose 16.03% to ₹3,368.81 crore in Q3 FY26 as against ₹2,903.38 crore in the same period of the previous fiscal year.

Its consolidated revenue from operations surged 13.49% to ₹15,520.54 crore in the December quarter of the financial year 2025-26, compared to ₹13,675.46 crore in the year-ago period.

The company's earnings before interest, tax, depreciation and amortisation (EBITDA) stood at ₹4,984.4 crore, reflecting an increase of 23.4% from ₹4,009 crore a year back.

About The Author

Journalist Kamal Joshi, former Republic TV and latestly editor, now associated with Upstox
Kamal Joshi is a business journalist who covers industries, markets, and IPOs. He is passionate about breaking news and enjoys playing pickleball, especially flexing his net play. He was previously associated with Republic TV and LatestLY.

Next Story